MDG1 — Medigene AG Share News
0.000.00%
Last trade - 00:00- €2.51m
- -€8.97m
- €6.03m
Brief: Medigene H1 Revenue Down At EUR 3.7 Million
Brief: Medigene Enters Phase I Clinical Development With Its Tcr-T Immunotherapy Mdg1021 In Hematological Cancers
Brief: Medigene Raises 2020 EBITDA Target
Brief: Medigene Q1 Total Revenue Down At Eur 1.40 Mln
Brief: Medigene FY Results Of Operations At EUR 9.8 Mln
Brief: Medigene Says Co, Iricor, Université De Montréal Sign Collaboration, Licensing Option On Novel Cancer Antigens
Brief: Medigene Cuts 2019 EBITDA Guidance
Brief: Medigene Announces Positive Final 2-Year Topline Data In DC Vaccine Phase I/II Trial In AML Patients
Brief: Medigene 9-Month EBITDA Loss Of EUR 18.6 Mln
Brief: Medigene H1 EBITDA Loss Of EUR 13.2 Mln
Brief: Medigene: Clinical Data From Interim Analysis Of Phase I/II Trial With DC Vaccine
Brief: Medigene: Clinical Trial Agreement For HA-1 TCR Immunotherapy MDG1021 With University Of Leiden
Brief: Medigene Q1 Net Loss Of EUR 5.7 Mln
Brief: Medigene Sells Remaining Rights And Inventories Of Veregen To Aresus
Brief: Medigene And Roivant Affiliate Cytovant Establish Strategic Partnership
Brief: Medigene FY Net Loss 17.0 Mln EUR, Up 7%
German stocks - Factors to watch on March 6
Brief: Deutsche Boerse Says Knorr-Bremse And Dialog Semiconductor New In MDAX
Brief: Medigene FY Total Revenues Amounted To EUR 7.8 Mln In 2018